Johnson & Johnson is going in hard on robotics, but its first big move here has still not paid off.
For $5bn up front Gilead has effectively gained access to the Belgian company’s pipeline, in a deal that will tie the US biotech to Galapagos for many years to come.
Innate swaps its lead candidate for Astra’s Lumoxiti in a bid to become a rare cancer player.
Pfizer is to push Exact’s cancer test in a deal that could “permanently alter the trajectory of Cologuard”.
Eisai deal to help Merck expand checkpoint inhibitor franchise.
Takeda's appetite for risk in early stage neuroscience could make it one to watch.